Fintel reports that on January 8, 2025, BTIG downgraded their outlook for Inari Medical (NasdaqGS:NARI) from Buy to Neutral.

Fintel reports that on January 7, 2025, Wells Fargo downgraded their outlook for Inari Medical (NasdaqGS:NARI) from ...

Stryker is in advanced discussions to acquire Inari Medical, a company producing devices for venous diseases. If successful, the acquisition, valued at nearly $3 billion, would enhance Stryker's ...

Stryker's acquisition of Inari for $4.9B enhances its neurovascular portfolio and boosts revenue growth by 50bp, with minimal ...

Inari Medical (NASDAQ:NARI – Free Report) had its price target increased by Piper Sandler from $52.00 to $80.00 in a report ...

Baird R W cut shares of Inari Medical (NASDAQ:NARI – Free Report) from a strong-buy rating to a hold rating in a research ...

Stryker acquires Inari Medical in a $4.9 billion deal, enhancing its vascular portfolio with innovative VTE treatments and a ...

After professing a hearty appetite for tuck-in M&A last year and signing a string of smaller deals, Stryker is now opening ...

Stryker plans to acquire Inari Medical for $4.9 billion to enhance its venous disease treatment portfolio. Inari, valued at nearly $3 billion, has seen increased interest amid growth in medical device ...

NARI continues to gain from its expanded product portfolio. The company's expansion in China and Japan bodes well.

Inari Medical (NARI – Research Report) received a Hold rating and price target from BTIG analyst Marie Thibault today. The company’s shares ...

Inari Medical (NARI – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Michael Sarcone ...